#Pharma: Glenmark today announced that it had found no new side effects in the post-marketing surveillance (PMS) study on Favipiravir in over 1,000 #COVID19 patients. Viswanath Pilla reports ⏬

https://www.moneycontrol.com/news/business/companies/no-new-side-effects-found-in-covid-19-antiviral-favipiravir-glenmark-7469011.html?utm_source=telegram&utm_medium=social

#Pharma: #Lupin has entered into a $248-million settlement agreement with the plaintiffs in an antitrust class-action #lawsuit against the company for the delayed launch of the anti-diabetic drug Glumetza generic in the US. Read ⏬

https://www.moneycontrol.com/news/business/companies/delayed-launch-of-glumetza-lupin-settles-case-for-248-million-7472811.html?utm_source=telegram&utm_medium=social

by Viswanath Pilla

#ICYMI | Rakesh Juhunjhunwala needs no introduction and is well known for his uncanny ability to spot the opportunity well before the others. His investments where he made a killing are well documented.

Titan is one of his investments that was in the news very recently for the sharp rally it witnessed and made fortunes for its investors like Jhunjhunwala.

https://www.moneycontrol.com/news/business/stocks/rakesh-jhunjhunwala-reduces-stake-in-pharma-major-lupin-7579151.html

#shareholding #rakeshjhunjhunwala #Pharma #Lupin #Stocks

Have you checked out #MCMinis yet? 🤔

They are quick explainers or short insights on topics that matter! They fit into the screenshot of your phone. 📲 It is that easy — and fast! ⚡️

Start exploring: https://moneycontrol.com/news/mcminis

#MCPersonalFinance #Pharma #MutualFund

#Budget2022WithMC: The government has decided to stop #Pharma companies from claiming the cost of various freebies and largesse offered to doctors as a business deduction from April 1

Read at 👇
https://www.moneycontrol.com/news/trends/health-trends/budget-2022-stops-pharma-companies-from-claiming-tax-cuts-on-freebies-to-doctors-8024681.html?utm_source=telegram&utm_medium=social

#MCOpinion: The #pandemic has turned into a godsend opportunity for #pharma giants. With #vaccines ruling the roost, the companies and the management hit a jackpot. But it all came with a costly tag.

Read more 👇
https://www.moneycontrol.com/news/opinion/moneycontrol-pro-panorama-vaccine-windfall-for-big-pharma-but-at-what-cost-8066211.html?utm_source=telegram&utm_medium=social

Aurobindo Pharma, one of India’s largest listed #pharma firms with a large contribution from global sales, is exploring a foray into the domestic formulations market and is actively looking at inorganic growth opportunities.

Read at 👇https://www.moneycontrol.com/news/business/aurobindo-pharma-eyes-domestic-market-foray-with-buyouts-targets-rs-1000-cr-domestic-formulation-sales-in-3-three-years-8123651.html?utm_source=telegram&utm_medium=social

OPPI President S Sridhar said it was time India moved away from #MakeInIndia to Discover in India to encourage innovation in #pharma sector & protecting intellectual property would be a good start.

Read the full interview at 👇
https://www.moneycontrol.com/news/business/set-up-special-high-court-benches-with-experts-to-resolve-patent-disputes-says-oppi-chief-sridhar-8260421.html?utm_source=telegram&utm_medium=social

#MCExclusive: The findings have prompted #pharma companies to pitch for a robust #OTC #drug policy in India so that self-treatment gets promoted and dependence on #doctors for minor health conditions is reduced.

Read more 👇
https://www.moneycontrol.com/news/trends/health-trends/exclusive-i-indians-spend-rs-35820-crore-a-year-on-minor-ailments-finds-novel-survey-by-pharma-body-8275381.html?utm_source=telegram&utm_medium=social

#MCExclusive ⚡️ Yet another blockbuster #pharma #IPO in the works as ChrysCapital backed Mankind Pharma, the maker of top selling Manforce Condoms has started listing prep and may be valued more than $8bn reports Ashwin Mohan.

Read the report 👇
https://www.moneycontrol.com/news/business/manforce-condoms-maker-mankind-pharma-starts-ipo-preparations-valuation-may-be-upwards-of-8-billion-8297751.html?utm_source=telegram&utm_medium=social

India needs extensive collaboration between industry & academia and also the development of an innovation infrastructure, says KG Ananthkrishnan, director general of #pharma body OPPI.

Read the full interview by Sumi Dutta at 🔻
https://www.moneycontrol.com/news/trends/health-trends/want-regulatory-reforms-to-expedite-launch-of-new-drugs-in-india-oppi-director-general-8343301.html?utm_source=telegram&utm_medium=social

#MCExclusive ⚡️ Sudarshan Jain, secretary-general of the Indian Pharmaceutical Alliance on the role played by the #pharma sector during the pandemic & the impact of the #RussiaUkraineWar.

Read at 👇
https://www.moneycontrol.com/news/business/interview-russia-ukraine-war-piles-stress-on-indian-pharma-industry-says-sudarshan-jain-of-ipa-8441841.html?utm_source=telegram&utm_medium=social

#DailyData 📊 India's #Pharma Exports 💊

#MarketsWithMC: Closing Bell 🔔 Except bank, all other sectoral indices ended in the red with #oil & #gas, metal, #pharma, realty, capital goods and IT index down 1-3%.

Stay tuned to this space for latest market updates 👇
https://www.moneycontrol.com/news/business/markets/share-market-live-updates-stock-market-today-may-25-latest-news-bse-nse-sensex-nifty-covid-coronavirus-bpcl-coal-india-nhpc-fortis-healthcare-interglobe-aviation-bata-india-grasim-minda-industries-8570411.html?utm_source=telegram&utm_medium=social

In the past, during a high #inflation period, #pharma sales have gone down, says #RKBaheti. But with the steps taken by the govt, he believes inflation will be reined in.

Read the full interview at 👇
https://www.moneycontrol.com/news/business/pharma-industry-faces-inflation-induced-slowdown-alembic-pharmaceutical-cfo-8587931.html?utm_source=telegram&utm_medium=social

#DailyVoice 🎙 #Pharma, #Auto, and #BFSI look attractive from medium-term perspective, especially after correction, says Darshan Engineer of Karma Capital.

Read at 👇
https://www.moneycontrol.com/news/business/markets/daily-voice-pharma-auto-and-bfsi-look-attractive-from-medium-term-perspective-especially-after-correction-says-darshan-engineer-of-karma-capital-8599341.html?utm_source=telegram&utm_medium=social

Early gains fizzle out as #Nifty edges back into the red. Broader #markets in the green; Mid & smallcap indices trade firm. #Pharma, IT, & PSU bank gains as #FMCG and auto #stocks lose.

⚡️Catch this chat between Nandita Khemka and Yatin Mota to understand the factors weighing down today's markets.

🔴 Live at 12.30 PM
🔗https://www.youtube.com/watch?v=MJSiqA6om7Q

#BudgetWithMC | The #pharma sector had urged the centre to prioritise schemes to enhance innovation and research along with tax incentives on drug development expenditure in the #budget.

Read on ⬇️
shorturl.at/ikrFG

#ShareKhan predicts in-line to marginal outperformance for the #pharma index going forward as valuations have become reasonable for large players such as #SunPharma, #ZydusLife, Dr Reddy’s and #TorrentPharma, as well as for niche India-focused players such as #AbbottIndia.

Read Here 👇🏻
https://bit.ly/3KDMb8m

#NewsAlert 🚨 Strides Pharma's Puducherry facility receives EIR from USFDA, reclassified from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI)

#StridePharma #Pharma #Puducherry #USFDA